Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 7/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24264549 | 0.86 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2THRBPLK1THRA | |
| SCHEMBL19719143 | 0.77 | CES2 (0.35) | KMT2AMAPTCYP2C19 | |
| SCHEMBL5448720 | 0.76 | AKT1 (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL18427854 | 0.76 | AKT1 (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL18560661 | 0.71 | ALDH5A1 (0.31) | MEN1KMT2ACYP2C9MAPTCYP2C19 | |
| SCHEMBL17149441 | 0.71 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2THRBPLK1THRA | |
| SCHEMBL14547106 | 0.71 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2THRBPLK1THRA | |
| SCHEMBL18789931 | 0.71 | — | — | |
| SCHEMBL9722329 | 0.70 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2THRBPLK1THRA | |
| SCHEMBL24217763 | 0.69 | THRB (0.47) | ALDH1A1SMN1; SMN2THRBKMT2ARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284635-A1 | METHOD FOR THE PROGNOSIS AND/OR TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA | EPI-C S.R.L. (IT) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284635-A1 | METHOD FOR THE PROGNOSIS AND/OR TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA | EZH2, KAT2A, EHMT2 | ALDH1A1 738/4885SMN1; SMN2 3186/4885THRB 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.